HRD testing: Definition, Uses, and Clinical Overview

HRD testing Introduction (What it is)

HRD testing looks for signs that a tumor has trouble repairing certain types of DNA damage.
HRD stands for homologous recombination deficiency, a problem in a key DNA repair pathway.
It is most commonly used in solid tumors, especially ovarian cancer, and sometimes breast, prostate, and pancreatic cancers.
The goal is to help clinicians understand tumor biology and support treatment planning.

Why HRD testing used (Purpose / benefits)

Cancer cells survive and grow by accumulating DNA changes (mutations) that allow uncontrolled division. Healthy cells have multiple systems to repair DNA damage. One major repair system is homologous recombination repair (HRR), which fixes serious DNA breaks accurately. When a tumor is HRD-positive, it suggests the tumor may rely on less accurate “backup” repair pathways.

HRD testing is used because it can help solve several practical problems in cancer care:

• Predicting sensitivity to certain treatments (predictive biomarker role). Tumors with HRD may be more vulnerable to therapies that exploit DNA repair weakness, such as PARP inhibitors in certain settings, and sometimes platinum-based chemotherapy (use varies by cancer type and stage).
• Refining risk–benefit decisions. When multiple treatment options exist, HRD status can be one factor (among stage, prior treatments, performance status, and patient goals) that supports a more individualized plan.
• Providing a structured summary of tumor DNA repair features. Some HRD results integrate multiple genomic signals (often called “genomic scars”) rather than relying on a single mutation.
• Supporting clinical trial eligibility. Many trials include HRD status or HRR-pathway alterations as an inclusion criterion, particularly in ovarian, breast, prostate, and pancreatic cancers.

Importantly, HRD testing does not diagnose cancer by itself and is not a general screening test for people without cancer. It is typically used after a cancer diagnosis to add biologic detail that may inform therapy choices.

Indications (When oncology clinicians use it)

Clinicians may consider HRD testing in situations such as:

• A confirmed epithelial ovarian, fallopian tube, or primary peritoneal cancer, where HRD status is often used to inform systemic therapy planning (varies by clinician and case).
• Breast cancer cases where tumor biology suggests DNA repair involvement (for example, certain high-risk or treatment-planning contexts; varies by subtype and stage).
• Metastatic prostate cancer or pancreatic cancer when evaluating for HRR pathway alterations and potential targeted-therapy approaches (varies by guideline, setting, and case).
• When a tumor is being profiled with next-generation sequencing (NGS) and the care team wants to assess HRD-related features as part of broader molecular testing.
• Considering or matching to a clinical trial that requires HRD-positive status or specific HRR gene alterations.
• Situations where distinguishing between germline (inherited) and somatic (tumor-only) DNA repair alterations could affect counseling, family risk assessment, or supportive services (handled through genetics pathways).

Contraindications / when it’s NOT ideal

HRD testing is not always appropriate or useful. Common limitations and “not ideal” situations include:

• Not a screening tool: It is generally not used to screen healthy people for cancer risk. Separate hereditary cancer genetic testing may be used for that purpose in selected families.
• Insufficient or poor-quality tumor material: Very small biopsies, low tumor cellularity, degraded DNA (for example from certain tissue processing), or heavy necrosis can make results unreliable or non-reportable.
• Cancer types where clinical utility is unclear: In some tumors, HRD status may not be validated for guiding therapy, or evidence may be evolving (varies by cancer type and stage).
• When another test better answers the question: For some decisions, testing for a specific actionable mutation (for example, a targeted therapy biomarker) may be more direct than a broader HRD assessment.
• Timing issues: If urgent treatment is needed and results will not return in time, clinicians may proceed based on clinical factors; HRD results may still be used later.
• Hematologic malignancies and many pediatric cancers: HRD frameworks are primarily used in solid tumors; applicability varies and may be limited in these settings.

How it works (Mechanism / physiology)

HRD testing is a diagnostic/predictive laboratory assessment, not a treatment. Its “mechanism” is the clinical pathway of detecting tumor DNA patterns that indicate deficient homologous recombination repair.

The relevant biology: homologous recombination repair (HRR)

• DNA double-strand breaks are among the most dangerous forms of DNA damage.
• HRR is an accurate repair pathway that uses a “template” (often the sister chromatid) to fix breaks.
• Key genes involved in HRR include BRCA1 and BRCA2, along with other HRR-associated genes (the exact gene list assessed depends on the test).

When HRR is impaired, a tumor may accumulate characteristic DNA patterns over time. HRD testing attempts to detect this state in two main ways:

1. Identifying HRR gene alterations
   This can include mutations or other changes in genes like BRCA1/2 (and sometimes a broader panel of HRR-related genes). Results may come from:

• Tumor (somatic) testing: looks at changes present in the cancer cells.
• Germline testing: looks for inherited variants, typically using blood or saliva, often coordinated through genetics services.

2. Measuring “genomic scarring” patterns
   Some HRD assays measure genomic features that reflect long-term DNA repair problems, such as:

• Loss of heterozygosity (LOH) patterns
• Other forms of chromosomal instability or copy-number changes (terminology and scoring vary by platform)

Onset, duration, and reversibility (closest relevant properties)

HRD testing does not have an “onset” like a medication. Instead:

• The HRD signal often reflects historical tumor evolution (genomic scarring can persist even if the tumor later changes).
• Tumor biology can evolve under treatment pressure, meaning HRD-related markers and treatment responsiveness may not be constant over time. Whether repeat testing is useful depends on the clinical context and available assays.

HRD testing Procedure overview (How it’s applied)

HRD testing is a testing workflow rather than a bedside procedure. A typical high-level pathway may look like this:

1. Evaluation/exam
   The oncology team confirms the diagnosis, reviews prior treatments, and clarifies the clinical question (for example, therapy selection, trial eligibility, or broader tumor profiling).

2. Imaging/biopsy/labs
   – Imaging helps define disease extent and guides biopsy decisions.
   – Tissue is obtained through surgery or biopsy, or sometimes a blood sample is used for circulating tumor DNA (ctDNA) testing (availability and performance vary by setting).

3. Staging
   Cancer stage is established using standard staging systems. HRD status complements staging but does not replace it.

4. Treatment planning
   Clinicians decide whether HRD testing is appropriate now, whether tumor testing, germline testing, or both are needed, and which laboratory method fits the clinical goal.

5. Testing and reporting
   – The laboratory extracts DNA, runs a sequencing and/or genomic-scar assay, and performs bioinformatic analysis.
   – The report typically includes an HRD call (positive/negative or score-based, depending on the platform) and may include details on specific gene alterations.

6. Response assessment
   If HRD results inform treatment choice, response is assessed using standard clinical tools such as symptoms, imaging, and tumor markers when relevant. HRD status itself is not a direct measure of response.

7. Follow-up/survivorship
   HRD results may remain in the medical record as part of the tumor’s profile and can be revisited if the cancer recurs or progresses, depending on the case.

Types / variations

HRD testing is not a single uniform test. Common variations include:

• Tumor-based HRD assays (tissue testing)
  Uses a sample from the tumor (biopsy or surgical specimen). This approach can evaluate tumor-specific changes directly, including somatic alterations.

• Blood-based approaches (ctDNA testing)
  Uses blood to look for tumor-derived DNA. It can be useful when tissue is limited, but performance and the ability to calculate HRD-related signatures vary by platform and situation.

• Gene-focused testing vs “genomic scar” testing

• Gene-focused: looks for mutations in BRCA1/2 and sometimes other HRR genes.

• Genomic scar/signature-based: integrates broader chromosomal patterns that suggest HRD even when a clear causative mutation is not found.

• Germline vs somatic testing (often complementary)

• Germline testing evaluates inherited variants that may affect both treatment planning and family risk assessment.

• Somatic testing evaluates tumor-only changes that can be actionable even without inherited risk.

• Diagnostic context: newly diagnosed vs recurrent/metastatic disease
  The reason for ordering HRD testing may differ by timing (for example, upfront planning versus selecting later-line therapies). Use varies by cancer type and stage.

• Setting: outpatient vs inpatient
  Testing is usually ordered outpatient as part of oncology planning, but inpatient ordering may occur during initial diagnosis or urgent workups.

Pros and cons

Pros:

• Can add biologic detail beyond standard pathology and staging.
• May help identify tumors more likely to benefit from DNA repair–targeting strategies (use varies by cancer type and stage).
• Can detect HRD features even when a single obvious driver mutation is not identified (depending on the assay).
• May support clinical trial matching and access to emerging therapies.
• Helps standardize communication about HRR pathway status across the care team.
• Can be incorporated into broader tumor profiling workflows (for example, NGS-based panels).

Cons:

• Not all cancers have validated, clinically actionable uses for HRD status (varies by cancer type and stage).
• Results can be limited by sample quality or low tumor content, leading to inconclusive findings.
• Different platforms may define HRD differently (score cutoffs, algorithms, and reporting can vary), which can complicate comparisons.
• An HRD-negative result does not guarantee a tumor will not respond to a given therapy; it is one factor among many.
• Turnaround time and insurance coverage can affect practical usefulness (varies by clinician and case).
• Tumor evolution over time can limit how well a single test reflects later disease behavior.

Aftercare & longevity

Because HRD testing is a laboratory assessment, “aftercare” focuses on how results are used and revisited over time rather than recovery from the test itself.

What tends to influence the real-world impact (“longevity” of usefulness) includes:

• Cancer type and stage: HRD status is more established in some cancers and clinical scenarios than others, and its role may change across lines of therapy.
• Tumor biology beyond HRD: Other biomarkers (and overall genomic complexity) can influence treatment options and outcomes.
• Treatment intensity and sequencing: Whether a patient receives surgery, chemotherapy, targeted therapy, radiation, or combinations affects outcomes; HRD is typically one input to planning.
• Adherence and supportive care: Managing side effects, nutrition, symptom control, and functional status can influence whether planned treatment can be delivered as intended.
• Comorbidities and overall health: Kidney, liver, bone marrow function, and other conditions can affect which treatments are feasible.
• Follow-up patterns: Regular monitoring can detect changes in disease status and clarify whether additional testing (including repeat tumor profiling) is reasonable in a given case.
• Access to specialized services: Genetics counseling, molecular tumor boards, and clinical trial programs can affect how fully HRD information is integrated into care.

If the cancer recurs or progresses, clinicians may reassess whether prior HRD testing remains representative or whether updated molecular testing might add value. This decision varies by clinician and case.

Alternatives / comparisons

HRD testing is one part of a broader landscape of oncology evaluation and treatment selection. High-level comparisons include:

• HRD testing vs BRCA-only testing
  BRCA testing focuses on BRCA1/2 alterations (germline and/or somatic). HRD testing may include BRCA plus additional HRR genes and/or genomic scarring patterns. In some settings, BRCA-only results may be sufficient for decision-making; in others, a broader HRD assessment may add context.

• HRD testing vs general tumor sequencing panels (NGS panels)
  Many NGS panels report actionable mutations (for targeted therapy selection) and may include HRR genes. A dedicated HRD assay may provide a more explicit HRD score or genomic-scar assessment, depending on the platform.

• HRD testing vs other biomarkers (e.g., MSI, TMB, PD-L1)
  These biomarkers address different biology (immune responsiveness or mismatch repair rather than homologous recombination). They are not interchangeable; clinicians may order multiple biomarkers to inform systemic therapy choices.

• HRD testing vs observation/active surveillance
  In cancers where observation is appropriate, HRD testing may not change management. The decision to test depends on whether results are expected to influence treatment planning.

• HRD testing in the context of treatment modalities
  HRD testing does not replace standard treatments such as surgery, radiation therapy, chemotherapy, targeted therapy, or immunotherapy. Instead, it can help refine systemic therapy choices in selected scenarios.

• Standard care vs clinical trials
  If standard options are limited or evidence is evolving, HRD status may help identify trial opportunities. Trial availability and eligibility vary by location and case.

HRD testing Common questions (FAQ)

Q: Is HRD testing the same as BRCA testing?
No. BRCA testing focuses on changes in BRCA1 and BRCA2, which are key HRR genes. HRD testing may include BRCA results but can also evaluate broader patterns suggesting HRR dysfunction, depending on the assay.

Q: Does HRD testing diagnose cancer or tell what stage it is?
HRD testing does not diagnose cancer and does not determine stage. Diagnosis and staging rely on pathology, imaging, and established staging systems. HRD results are typically used to add tumor biology information after diagnosis.

Q: Will HRD testing be painful or require anesthesia?
The HRD analysis itself is done in a laboratory and is not felt by the patient. Discomfort depends on how the sample is collected: surgery and biopsies may involve anesthesia or local numbing, while blood draws are usually brief.

Q: How long does HRD testing take to come back?
Turnaround time varies by laboratory, sample type, and whether additional sequencing or confirmatory steps are needed. In practice, results may take from days to weeks, and timing can affect whether it informs immediate decisions.

Q: What does “HRD-positive” mean in plain language?
It generally means the tumor shows evidence of impaired homologous recombination DNA repair. In some cancers and treatment settings, that information may support the use of therapies designed to exploit DNA repair weakness. The implications vary by cancer type and stage.

Q: If my tumor is HRD-negative, does that mean targeted therapy won’t work?
Not necessarily. HRD-negative means the test did not find evidence meeting that assay’s definition of HRD. Treatment response depends on many factors, and other biomarkers or clinical features may still support targeted therapies or other options.

Q: Is HRD testing safe? Are there side effects?
The lab test has no physical side effects. Risks relate to sample collection (for example, biopsy-related bleeding, pain, or infection risk), which vary by procedure and patient factors.

Q: How much does HRD testing cost?
Costs vary widely based on the test type, insurance coverage, country/region, and whether tumor testing, germline testing, or both are ordered. Some patients may encounter prior authorization or out-of-pocket costs, depending on coverage policies.

Q: Will HRD testing affect fertility or pregnancy?
The test itself does not affect fertility. However, HRD-related results can influence treatment planning, and some cancer treatments can affect fertility. Fertility preservation and pregnancy-related considerations are typically addressed as part of oncology care planning when relevant.

Q: Will I need time off work or activity restrictions for HRD testing?
The testing process usually does not require downtime. Any activity limits depend on how the sample is collected (for example, recovery after surgery or biopsy) and the overall treatment plan rather than the HRD analysis.

Q: Will I need repeat HRD testing later?
Sometimes, but not always. Because tumors can evolve and different tests measure different features, clinicians may consider updated molecular testing at recurrence or progression, especially if new treatment options or trials are being considered. This varies by clinician and case.